Prevention of chemotherapy-induced menopause by temporary ovarian suppression with triptorelin vs. control in young breast cancer patients. A randomized phase III multicenter study [PROMISE].
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Triptorelin (Primary)
- Indications Primary ovarian insufficiency
- Focus Therapeutic Use
- Acronyms PROMISE-GIM6
- 26 Jun 2013 Biomarkers information updated
- 20 Jul 2011 Results published in JAMA: the Journal of the American Medical Association.
- 20 Jul 2011 Primary endpoint 'Disease-occurrence-rate' has been met.